Skip to main content

Table 5 Significant effects of poly-miRTS on adverse events after chemotherapy of AML patients (Chi square/Fisher’s exact test)

From: Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients

SNP genotypes

Total (n)

Adverse events

 

OR (95% CI)

Yes (n, %)

No (n)

rs3743527

 

Myelosuppression

   

 CC

63

48 (76.2)

15

 

1.00 (reference)

 TC

108

85 (78.7)

23

0.703

1.155 (0.51–2.422)

 TT

35

34 (97.1)

1

0.007

10.625 (1.339–84.317)

 TC+TTa

143

119 (83.2)

24

0.236

1.549 (0.749–3.206)

rs212091

 

Myelosuppression

   

 AA

122

107 (87.7)

15

 

1.00 (reference)

 AG

72

51 (70.8)

21

0.003

0.340 (0.162–0.715)

 GG

12

9 (75.0)

3

0.431

0.421 (0.102–1.729)

 AG+GGa

84

60 (71.4)

24

0.003

0.350 (0.171–0.719)

rs212090

 

Gastrointestinal reaction

   

 TT

135

37 (27.4)

98

 

1.00 (reference)

 AT

63

29 (46.0)

34

0.010

2.259 (1.211–4.213)

 AA

8

0 (0)

8

0.192

–

 AA+ATa

71

29 (40.8)

42

0.049

1.829 (0.998–3.35)

rs9024

 

Cardiotoxicity

   

 GG

123

2 (1.6)

121

 

1.00 (reference)

 GA

69

7 (10.1)

62

0.020

6.831 (1.378–33.866)

 AA

14

2 (14.3)

12

0.052

10.083 (1.301–78.151)

 GA+AAa

83

9 (10.8)

74

0.010

7.358 (1.547–34.989)

  1. Italic values indicate statistical significance
  2. aThe dominant model